The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib

The FDA approved irreversible inhibitor of ERBB1/2/4, neratinib, was recently shown to rapidly down-regulate the expression of ERBB1/2/4 as well as the levels of c-MET and mutant K-RAS via autophagic degradation. In the present studies, in a dose-dependent fashion, neratinib reduced the expression l...

Descripción completa

Detalles Bibliográficos
Autores principales: Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Kirkwood, John, Sander, Cindy, Avogadri-Connors, Francesca, Cutler Jr, Richard E., Lalani, Alshad S., Dent, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790370/
https://www.ncbi.nlm.nih.gov/pubmed/29219657
http://dx.doi.org/10.1080/15384047.2017.1394556

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790370/
https://www.ncbi.nlm.nih.gov/pubmed/29219657
http://dx.doi.org/10.1080/15384047.2017.1394556

Ejemplares similares